Atea Pharmaceuticals (AVIR) News Today $3.56 +0.05 (+1.28%) As of 10:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Atea Pharmaceuticals’ Earnings Call Highlights HCV ProgressAugust 13 at 3:50 AM | msn.comAtea Pharmaceuticals (NASDAQ:AVIR) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPSAugust 11 at 7:42 PM | marketbeat.comAtea Pharmaceuticals (NASDAQ:AVIR) Stock Rating Lowered by Wall Street ZenAugust 10 at 2:56 AM | marketbeat.comAtea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comAtea (AVIR) Q2 Loss Narrows 8%August 7, 2025 | fool.comAtea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comCM Management LLC Has $1.50 Million Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)August 7, 2025 | marketbeat.comAtea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025July 31, 2025 | globenewswire.comAtea Pharmaceuticals (AVIR) Projected to Post Earnings on WednesdayJuly 30, 2025 | marketbeat.comAtea Pharmaceuticals Insiders Placed Bullish Bets Worth US$5.40mJuly 24, 2025 | finance.yahoo.comPeapod Lane Capital LLC Buys 123,479 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)July 10, 2025 | marketbeat.comAVIR Atea Pharmaceuticals, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comAtea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North AmericaJune 24, 2025 | globenewswire.comHere's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn SituationJune 17, 2025 | finance.yahoo.comTwo Sigma Advisers LP Sells 88,800 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)May 31, 2025 | marketbeat.comBNP Paribas Financial Markets Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)May 28, 2025 | marketbeat.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Holdings Increased by Tang Capital Management LLCMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Lowers Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)May 19, 2025 | marketbeat.comNewtyn Management LLC Purchases 200,000 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)May 16, 2025 | marketbeat.comDimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)May 16, 2025 | marketbeat.comAtea Pharmaceuticals (NASDAQ:AVIR) Issues Earnings Results, Beats Expectations By $0.01 EPSMay 14, 2025 | marketbeat.comAtea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comAtea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comAtea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025May 7, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stake Lessened by Almitas Capital LLCMay 4, 2025 | marketbeat.comAtea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025May 1, 2025 | globenewswire.comJPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)April 28, 2025 | marketbeat.comRBF Capital LLC Has $183,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)April 26, 2025 | marketbeat.comAtea Pharmaceuticals announces results from phase 2 study of bemnifosbuvirApril 24, 2025 | markets.businessinsider.comAtea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025April 23, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc.April 20, 2025 | marketbeat.comAtea Pharmaceuticals says strategic alternatives process ‘ongoing’April 17, 2025 | markets.businessinsider.comAtea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase ProgramApril 17, 2025 | globenewswire.comMorgan Stanley Remains a Hold on Atea Pharmaceuticals (AVIR)April 13, 2025 | markets.businessinsider.comMorgan Stanley Has Lowered Expectations for Atea Pharmaceuticals (NASDAQ:AVIR) Stock PriceApril 13, 2025 | marketbeat.comAtea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 studyApril 9, 2025 | msn.comADAR1 Capital Management LLC Invests $368,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)April 9, 2025 | marketbeat.comAtea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusApril 9, 2025 | globenewswire.comDriver Notifies Atea Pharmaceuticals of Withdrawal of Notice of NominationMarch 31, 2025 | globenewswire.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder ValueMarch 30, 2025 | finanznachrichten.deAtea Pharmaceuticals takes steps to boost shareholder valueMarch 28, 2025 | investing.comAtea Pharmaceuticals cuts workforce by ~25% in Q1March 27, 2025 | msn.comAtea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder ValueMarch 26, 2025 | globenewswire.comThe Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of DirectorsMarch 26, 2025 | finance.yahoo.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Issues Statement Regarding Director NominationsMarch 22, 2025 | finanznachrichten.deAtea Pharmaceuticals Issues Statement Regarding Director NominationsMarch 21, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (AVIR): A Bull Case TheoryMarch 21, 2025 | insidermonkey.comAtea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025March 19, 2025 | globenewswire.comWhat is William Blair's Forecast for AVIR Q1 Earnings?March 10, 2025 | marketbeat.comAtea Pharmaceuticals Reports Successful FDA Meeting and Plans Phase 3 Program for Hepatitis C TreatmentMarch 8, 2025 | nasdaq.com Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address AVIR Media Mentions By Week AVIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVIR News Sentiment▼0.690.75▲Average Medical News Sentiment AVIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVIR Articles This Week▼92▲AVIR Articles Average Week Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Harrow News Praxis Precision Medicines News Avadel Pharmaceuticals News Phibro Animal Health News Pharvaris News Ardelyx News Structure Therapeutics News Amphastar Pharmaceuticals News Verve Therapeutics News Spyre Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVIR) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access